Signal from the log
Thryv Therapeutics
30 M$ · Series B · United States · Biotech
Thryv Therapeutics développe THRV-1268, un inhibiteur de la kinase SGK1, contre le syndrome du QT long, un trouble héréditaire du rythme cardiaque, et l'insuffisance cardiaque. La série B, menée par la société de recherche clinique InClin, finance un essai de phase 2a qui ouvrira début 2027.
Verified
Announced on , logged by the watch of 3 November 2026.
- Operation
- Funding round
- Announced amount
- 30 M$
- Stage
- Series B
- Country
- United States
- Sector
- Biotech
What the log says
Editorial note, in French
Communiqué ouvert, montant relu et fonds nommés.
The investors
Led by InClin
Provenance
Source prnewswire
Logged on 3 November 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.